FDA BRIEF: week of October 24, 2016
FDA is working with hospitals to modernize data collection about medical devices
Hospital staff use a variety of medical devices, help identify new safety problems with devices, use technologies in real-world setting of clinical practice
FDA improving work with hospitals to modernize and streamline data collection about medical devices – with focus on SAFETY
(1) Medical device reporting from hospitals
- Must report device-related serious injuries/ device-related deaths to both FDA and the manufacture
- However, this is passive surveillance
(2) MedSun (the Medical Product Safety Network) with hospitals
- Understand and report on device use in the real-world environmen
- But limited added value, unnecessary costs and resources
- Not enforced universal reporting requirements
High-profile device safety issues occurring in hospitals in 2015
- Inspections at 17 hospitals- related to spread of uterine cancer from use of morcellators or contaminated duodenoscopes
Lessons learned from inspections
- Didn’t submit required reports for deaths or serious injuries
- Didn’t not have adequate procedures for reporting device-related death or serious injury events to FDA/manufacturers
- Need better way to work with hospitals to get the real-world information
Next Steps to effectively work with hospitals
- Participate in the National Evaluation System for health Technology NEST
- Asses current reporting requirements
- Use effective modern tools for surveillance
- Public workshop to solicit input and advice on improving hospital-based surveillance systems
- Work with the Association of American Medical Colleges and the American Hospital Association
FDA’s Opioids Action Plan: A Midyear Checkup
By: Robert M. Califf, M.D., FDA Commissioner
FDA working with Surgeon General’s office (TurnTheTideRx campaign to address Opioid epidemic
Conducted tours of areas hard-hit by the opioid crisis in TN, WV, KY
Opioid education – including training during medical school and residency and greater public awareness far and wide – is a key component in fighting the opioid epidemic
FDA milestones so far include
- Developing warning and safety information for immediate release opioids
- Better understand long-term safety of using extended release/long acting opioids
- Guidance on development of generics with abuse-deterrent formulations
- Advice from National Academy of Science Engineering and Medicine on balance of patients needs vs. opioid misuse and abuse
- Supporting increased access to naloxone
- Launch competition to create Mobile App
- Approve first implantable treatment for opioid dependence.
FDA will continue work for judicious and responsible use of opioids
By: Douglas C. Throckmorton, M.D., Deputy Center Director for Regulatory Programs, CDER
7 approved opioid formulations with abuse-deterrent (AD) properties
- Tablets/Capsules designed to deter abusers from crushing them into a powder for swallowing, snorting or injecting to create a faster, more intense high.
- Manufacturers submitted study data demonstrating products are expected to deter abuse.
- Labeling clearly states the product’s abuse-deterrent properties
“Abuse-deterrent” (AD) vs.abuse-proof
- AD will always have some potential for abuse
- FDA requires further post-marketing evaluation of AD products
Generic abuse-deterrent development encouraged
- Draft guidance for AD generics
- public discussion of the topic next Monday and Tuesday
- Opioid action plan
Depression: FDA-Approved Medications May Help
Treatment with Medication
Antidepressants: Change neurotransmitters—primarily serotonin, norepinephrine, and dopamine—which are involved in regulating mood.
- selective serotonin reuptake inhibitors (SSRIs): Prozac (fluoxetine), Celexa (citalopram), Paxil (paroxetine)
- serotonin norepinephrine reuptake inhibitors (SNRIs): Effexor (venlafaxine), Cymbalta (duloxetine)
- tricyclic antidepressants (TCAs): Elavil (amitriptyline), Tofranil (imipramine), Pamelor (nortriptyline)
- monoamine oxidase inhibitors (MAOIs): Nardil (phenelzine) and Parnate (tranylcypromine)
- Other: Remeron (mirtazapine), Wellbutrin (bupropion)
Antidepressant Effectiveness
- Regular doses several weeks
- Significant percentage may not respond to prescribed antidepressant; switching to a different medication or adding another medication can sometimes help treat symptoms
- Some may not respond to medication
Common side effects
- Nausea and vomiting
- Weight gain
- Diarrhea
- Sleep disturbances
- Sexual problems